Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2014

01-10-2014 | Melanomas

The Influence of Sentinel Lymph Node Biopsy on Survival for Intermediate-Thickness Melanoma

Authors: Swapnil D. Kachare, MD, Jason Brinkley, PhD, Jan H. Wong, MD, Nasreen A. Vohra, MD, Emmanuel E. Zervos, MD, Timothy L. Fitzgerald, MD

Published in: Annals of Surgical Oncology | Issue 11/2014

Login to get access

Abstract

Background

The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) failed to demonstrate a survival advantage for sentinel lymph node biopsy (SNB) in melanoma. This may have been secondary to inadequate statistical power. This study was designed to determine the impact of SNB on melanoma-specific survival (MSS) in a larger patient cohort.

Methods

From 2003–2008, patients with tumors 1–4 mm in thickness and clinically negative nodes were identified within the SEER registry. Propensity score was used to create two matched cohorts: those who underwent a wide excision with SNB or wide excision alone.

Result

A total of 15,274 met inclusion criteria and 7,910 comprised the match cohort. Average age was 67.4 years. The majority were male (62.3 %) and white (97.2 %). Primary tumors were most frequently nonulcerated (77.1 %), located on the extremity (42.3 %), and T2 (64.1 %). There were 3,955 patients in both the SNB and observation groups. There was no significant difference in gender, ethnicity, ulceration status, primary site, or T-classification between the groups. Improved 5-year MSS was associated with SNB (85.7 vs. 84.0 %), female gender (88.3 vs. 82.7 %), absence of ulceration (87.5 vs. 75.7 %), extremity location (87.4 %), T2 disease (88.6 vs. 77.9 %), and a negative SNB (88.9 vs. 64.8 %). The relationships between observation [hazard ratio (HR) 1.18], male gender (HR 1.33), ulceration (HR 1.77), head-and-neck location (HR 1.34), and T3 disease (HR 1.82) persisted on multivariate analysis.

Conclusions

Status of the sentinel node is the strongest predictor of survival in patients with intermediate thickness melanoma. SNB compared with observation was associated with a modest survival advantage.
Literature
1.
Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978;41(3):948–56.PubMedCrossRef
2.
Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49(11):2420–30.PubMedCrossRef
3.
Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7(2):87–97.PubMedCrossRef
4.
Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3):255–63; discussion 263–6.PubMedCrossRefPubMedCentral
5.
Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793–6.PubMedCrossRef
6.
7.
Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.PubMedCrossRef
8.
9.
Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143(9):892–9; discussion 899–900.PubMedCrossRefPubMedCentral
10.
Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. AJCC cancer staging manual, 7th ed. Philadelphia: Lippincott-Raven; 2010.
11.
Rosenbaum PR. Observational studies, 2nd ed. New York: Springer-Verlag; 2002.CrossRef
12.
Perraillon MC. Matching with propensity scores to reduce bias in observational studies. NESUG. 2006:1–10.
13.
D’Agostino RH. Propensity score methods for bias reduction in the comparison of a treatment of a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef
14.
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9.PubMedCrossRef
15.
Cascinelli N. WHO declares lymphatic mapping to be standard of care for melanoma. Oncology. 1999;13:288.
16.
Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15(3):670–3.PubMedCrossRefPubMedCentral
17.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.PubMedCrossRefPubMedCentral
18.
Iwashyna TJL, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992–8.PubMedCrossRef
19.
Sun M, Trinh QD, Bianchi M, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol. 2012;61:725–731.PubMedCrossRef
20.
Abdollah F, Sun M, Schmitges J, et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol. 2011;60:920–30.PubMedCrossRef
21.
Reeve BB, Smith AW, Arora NK, Hays RD. Reducing bias in cancer research: application of propensity score matching. Health Care Financ Rev. 2008;29(4):69–80.PubMed
22.
Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.PubMedCrossRef
23.
Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2–pT3). Ann Surg Oncol. 2008;15(8):2223–34.PubMedCrossRef
24.
25.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976–83.PubMed
26.
Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes—one institution’s experience. Melanoma Res. 2003;13(1):35–43.PubMedCrossRef
27.
Fadaki N, Li R, Parrett B, et al. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome? Ann Surg Oncol. 2013;20(9):3089–97.PubMedCrossRef
28.
Chao C, Wong SL, Edwards MJ, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol. 2003;10(1):21–6.PubMedCrossRef
29.
Gimotty PA, Yoon F, Hammond R, Rosenbaum P, Guerry D. Therapeutic effect of sentinel lymph node biopsy in melanoma remains an open question. J Clin Oncol. 2009;27(26):4236–8.PubMedCrossRefPubMedCentral
30.
Grob JJ, Dreno B, Salmoniere P, et al. Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastasis. Lancet. 1998;351:1905–10.PubMedCrossRef
31.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.PubMed
32.
Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control. 2005;12(4):223–9.PubMed
33.
Winkelmayer WC, Kurth T. Propensity scores: help or hype? Nephrol Dial Transplant. 2004;19(7):1671–73.PubMedCrossRef
34.
Kachare SD, Agle SC, Englert ZP, et al. Malignant blue nevus: clinicopathologically similar to melanoma. Am Surg. 2013;79(7):651–6.PubMed
35.
Kachare SD, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. Sentinel lymph node biopsy is associated with improved survival in Merkel cell carcinoma. Ann Surg Oncol. 2014;21(5):1624–30.PubMedCrossRef
36.
Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol. 2007;25(9):1043–7.PubMedCrossRef
37.
Torjesen I. Sentinel node biopsy for melanoma: unnecessary treatment? BMJ. 2013;8:1.
38.
Metadata
Title
The Influence of Sentinel Lymph Node Biopsy on Survival for Intermediate-Thickness Melanoma
Authors
Swapnil D. Kachare, MD
Jason Brinkley, PhD
Jan H. Wong, MD
Nasreen A. Vohra, MD
Emmanuel E. Zervos, MD
Timothy L. Fitzgerald, MD
Publication date
01-10-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 11/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3954-5

Other articles of this Issue 11/2014

Annals of Surgical Oncology 11/2014 Go to the issue

Breast Oncology

Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing

Breast Oncology

Contralateral Prophylactic Mastectomy and Survival: An Ongoing Challenge

Colorectal Cancer

Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer

Gastrointestinal Oncology

A Systematic Review and Meta-analysis Comparing Pancreaticoduodenectomy Versus Limited Resection for Duodenal Gastrointestinal Stromal Tumors

Colorectal Cancer

Documentation of Quality of Care Data for Colon Cancer Surgery: Comparison of Synoptic and Dictated Operative Reports

Gynecologic Oncology

Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study